Common pharmaceutical issues and review considerations for biologics license applications of antibody products

ZHAO Jing, WEI Wei, HE Wu

PDF(1065 KB)
PDF(1065 KB)
Chinese Journal of New Drugs ›› 2025, Vol. 34 ›› Issue (6) : 571-578. DOI: 10.20251/j.cnki.1003-3734.2025.06.003

Common pharmaceutical issues and review considerations for biologics license applications of antibody products

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 34(6): 571-578 https://doi.org/10.20251/j.cnki.1003-3734.2025.06.003

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1065 KB)

Accesses

Citation

Detail
Sections
Recommended
Total:
Copyright © Chinese Journal of New Drugs, All Rights Reserved.
Tel: 010-52722697 | 010-52723707
　 Powered by Beijing Magtech Co., Ltd.

/

〈 〉